CRISPR Therapeutics AG (CRSP) Income from Non-Controlling Interests (2015 - 2019)

CRISPR Therapeutics AG has disclosed Income from Non-Controlling Interests across 5 years of filings, most recently posting $14.2 million for Q1 2019.

• Income from Non-Controlling Interests for Q1 2019 came in at $14.2 million, up 13.6% year-over-year; the trailing twelve-month figure through Mar 2019 was $54.4 million (up 25.93% YoY), and the FY2018 annual result was $52.5 million, up 45.03% from the prior year.
• Income from Non-Controlling Interests came in at $14.2 million for Q1 2019 at CRISPR Therapeutics AG, up from $14.1 million in the prior quarter.
• In the past five years, Income from Non-Controlling Interests ranged from a high of $14.2 million in Q1 2019 to a low of -$16000.0 in Q4 2015.
• The 5-year median for Income from Non-Controlling Interests is $9.0 million (2017), against an average of $6.9 million.
• Across the five-year window, Income from Non-Controlling Interests sank 1300.0% in 2016 and soared 1150100.0% in 2017, its largest moves.
• CRISPR Therapeutics AG's Income from Non-Controlling Interests stood at -$16000.0 in 2015, then jumped by 93.75% to -$1000.0 in 2016, then jumped by 1150100.0% to $11.5 million in 2017, then increased by 22.61% to $14.1 million in 2018, then grew by 0.71% to $14.2 million in 2019.
• The last three Income from Non-Controlling Interests figures came in at $14.2 million (Q1 2019), $14.1 million (Q4 2018), and $12.6 million (Q3 2018), per Business Quant data.